Dermatology AI Compliance in California (2026)
Dermatology was one of the first specialties to adopt AI for clinical image analysis, and it remains one of the most active areas of AI development in healthcare. California's AB 489, AB 3030, and SB 942 create specific obligations for practices deploying these tools.
AI in Dermatology: The Compliance Landscape
Dermatology AI tools range from FDA-cleared diagnostic aids for lesion classification to consumer-facing skin analysis apps to teledermatology platforms that deliver AI-assisted assessments at scale. Each deployment model carries distinct compliance obligations under California law.
The core risk in dermatology AI is that patients receiving AI-generated assessments of potentially malignant lesions may not understand they are receiving AI output rather than a physician's clinical judgment. AB 489 addresses this directly.
AB 489: Disclosures for Patient-Facing AI Analysis Tools
Any AI system that delivers skin analysis results, lesion assessments, or clinical recommendations directly to a patient must comply with AB 489. Common triggers in dermatology include:
- Teledermatology apps — patient-facing apps that analyze uploaded photos and return AI-generated assessments
- Patient portal integrations — AI tools embedded in patient portals that deliver preliminary assessment results
- Consumer skin screening tools — apps marketed to consumers that classify moles or skin conditions
- Virtual consultation pre-screening — AI intake tools that assess photos before a provider reviews them
The disclosure must appear before the AI delivers any clinical content. Using language like "powered by AI" in small print at the bottom of a screen does not satisfy the requirement.
Compliance Tip
AI skin analysis tools that use avatar interfaces (e.g., a virtual "Dr. Smith" reviewing your results) must not depict the AI avatar with clinical signifiers such as a white coat, stethoscope, or medical title. This constitutes prohibited clinical camouflage under AB 489.
AB 3030: AI-Generated Clinical Communications
AB 3030 applies when generative AI is used to draft patient-facing clinical content. In dermatology practices, the most common triggers are:
- AI-drafted biopsy result summaries sent to patients through the patient portal
- Automated post-procedure care instructions generated by an LLM
- AI-written treatment plan summaries for conditions like acne, psoriasis, or eczema
- Automated follow-up messages after phototherapy or cosmetic procedures
Practices must either implement a physician review step before sending AI-generated content, or add a specific AB 3030 disclosure to every automated communication explaining that the content was AI-generated and not reviewed by a dermatologist — with clear instructions for reaching the practice.
SB 942: Watermarking for High-Volume Platforms
Teledermatology platforms and health networks that serve more than 1 million monthly California users face additional obligations under SB 942. AI-generated content — including automated patient reports and educational materials — must carry manifest (visible) and latent (embedded) provenance markers indicating it was produced by AI.
Individual dermatology practices rarely reach the 1 million user threshold, but platform vendors who supply AI tools to multiple practices may cross it and must comply at the platform level.
Recommended Compliance Checklist for Dermatology Practices
- Add AB 489 disclosures to all patient-facing AI skin analysis tools, including teledermatology apps
- Audit AI avatar interfaces for prohibited clinical camouflage
- Map all AI-generated communications (biopsy results, care instructions, follow-ups) and assign them to a review or disclosure workflow
- Implement a "Contact Your Dermatologist" pathway in all AI-generated communications
- Review vendor contracts for AI tools — ensure vendors are complying with California law and update contracts as needed
- Confirm whether your patient volume triggers SB 942 obligations at the platform level
Frequently Asked Questions
Does an AI skin lesion analysis tool require a disclosure under AB 489?
Yes. If a dermatology practice deploys an AI tool that communicates directly with patients — such as a teledermatology app or patient portal feature that analyzes uploaded photos and delivers assessment results — it must disclose at the start of the interaction that the system is an AI, not a licensed dermatologist. The disclosure must appear before any clinical assessment is delivered.
Do AI-generated follow-up care summaries in dermatology require AB 3030 disclosures?
Yes. If a generative AI system drafts post-procedure care instructions, biopsy result explanations, or treatment plan summaries that are sent to patients without a dermatologist's review, AB 3030 requires a specific disclosure stating the content was AI-generated and was not reviewed by a human provider, along with instructions for contacting the practice.
Does SB 942 apply to AI-generated dermatology patient education content?
SB 942 applies to large platforms with over 1 million monthly California users that generate AI content. A single dermatology practice is unlikely to meet that threshold. However, teledermatology platforms or health systems that generate AI health content at scale and reach that user threshold must apply manifest and latent watermarking to AI-generated content.
Generate Your AB 3030 Disclosure
Use our free tool to create compliant disclosure language for your dermatology practice's AI communications.
Open Disclosure Generator →